NCT07269470
Phase I/II Study Assessing the Safety and Efficacy of Dasatinib in Combination With Ropeginterferon in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 9 versions: 5 with changes below, 4 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Notable Phase changed: Phase 2 → Phase 1/2
- Study title revised
- Notable Eligibility criteria expanded, about 6 words
- Notable Recruitment opened
- Start date changed from estimate of Nov 1, 2026 to Jul 13, 2026
- Site details revised
- Notable Start date: May 1, 2026 to Nov 1, 2026v4
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Safety and Adverse Events (AEs)
Timeframe: Through study completion; an average of 1 year
Arms and interventions
Phase 2 Treatment with Dasatinib (PO) + Ropeginterferon (SC)Experimental
Participants will receive treatment on an outpatient basis.
Drugs: Dasatinib, Ropeginterferon alfa-2b (P1101)
Sites
1 site in 1 country
- The University of Texas M. D. Anderson Cancer CenterHouston, Texas, United States